Literature DB >> 9259009

Role of morphine glucuronide metabolites in morphine dependence in the rat.

A Salem1, W Hope.   

Abstract

Concentrations of morphine and its 3- and 6-glucuronide metabolites (M3G and M6G) in plasma, brain, and urine of rats exposed to morphine for either 24 or 48 h were measured using high-performance liquid chromatography. In another group of morphine-treated rats, the intensity of naloxone-precipitated withdrawal behaviours was monitored at 24 and 48 h. The behavioural effects of M3G in opiate-naive and opiate-dependent rats were also investigated. Morphine was present in plasma, urine, and brain at 24 and 48 h, whereas M3G was detected in plasma and urine only. M6G was not present in detectable quantities in either plasma, urine, or brain. Although plasma concentrations of M3G were similar in both time groups, rats treated for 48 h had significantly larger quantities of M3G in their urine than did the other treatment groups. The incidence of withdrawal behaviour was significantly higher in animals exposed to morphine for 48 h than in those with only 24 h of exposure, M3G had no behavioural effects in the opiate-naive rats and did not precipitate an opiate-abstinence syndrome in morphine-dependent rats. From these results, it was concluded that although M3G is the major product formed by morphine breakdown in rats, it is unlikely that it is involved in the development of morphine dependence in this species.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9259009     DOI: 10.1016/s0091-3057(96)00471-6

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  7 in total

Review 1.  Morphine as a treatment of cancer-induced pain-is it safe? A review of in vivo studies and mechanisms.

Authors:  David Brinkman; Jiang H Wang; Henry P Redmond
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-09-20       Impact factor: 3.000

2.  Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis.

Authors:  Anika L Dzierlenga; John D Clarke; Tiffanie L Hargraves; Garrett R Ainslie; Todd W Vanderah; Mary F Paine; Nathan J Cherrington
Journal:  J Pharmacol Exp Ther       Date:  2014-12-15       Impact factor: 4.030

Review 3.  Morphine-3-Glucuronide, Physiology and Behavior.

Authors:  Florian Gabel; Volodya Hovhannisyan; Abdel-Karim Berkati; Yannick Goumon
Journal:  Front Mol Neurosci       Date:  2022-05-12       Impact factor: 6.261

4.  Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux.

Authors:  D Groenendaal; J Freijer; D de Mik; M R Bouw; M Danhof; E C M de Lange
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

5.  Direct nose-to-brain transfer of morphine after nasal administration to rats.

Authors:  Ulrika Espefält Westin; Emma Boström; Johan Gråsjö; Margareta Hammarlund-Udenaes; Erik Björk
Journal:  Pharm Res       Date:  2006-02-25       Impact factor: 4.200

6.  Pharmacokinetics of Morphine in Rats with Adjuvant-induced Arthritis.

Authors:  Yoshiaki Kimura; Mika Shibata; Mika Tamada; Noriyuki Ozaki; Kunizo Arai
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

7.  Distribution of opiate alkaloids in brain tissue of experimental animals.

Authors:  Maja Djurendic-Brenesel; Vladimir Pilija; Neda Mimica-Dukic; Branislav Budakov; Stanko Cvjeticanin
Journal:  Interdiscip Toxicol       Date:  2012-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.